CN102648969A - 固肾复方中药制剂 - Google Patents
固肾复方中药制剂 Download PDFInfo
- Publication number
- CN102648969A CN102648969A CN2012101218936A CN201210121893A CN102648969A CN 102648969 A CN102648969 A CN 102648969A CN 2012101218936 A CN2012101218936 A CN 2012101218936A CN 201210121893 A CN201210121893 A CN 201210121893A CN 102648969 A CN102648969 A CN 102648969A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- kidney
- chinese medicine
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 210000003734 kidney Anatomy 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 230000003014 reinforcing effect Effects 0.000 title abstract description 6
- 244000268590 Euryale ferox Species 0.000 claims abstract description 11
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 210000000582 semen Anatomy 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 13
- 241000237903 Hirudo Species 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 10
- 241000180649 Panax notoginseng Species 0.000 claims description 10
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 206010018367 Glomerulonephritis chronic Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 14
- 210000000952 spleen Anatomy 0.000 abstract description 10
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 5
- 208000032843 Hemorrhage Diseases 0.000 abstract description 4
- 230000000740 bleeding effect Effects 0.000 abstract description 4
- 206010027514 Metrorrhagia Diseases 0.000 abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 206010015866 Extravasation Diseases 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 240000007171 Imperata cylindrica Species 0.000 abstract 1
- 241000123069 Ocyurus chrysurus Species 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 235000007164 Oryza sativa Nutrition 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 206010039424 Salivary hypersecretion Diseases 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000019606 astringent taste Nutrition 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000036251 extravasation Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 235000009566 rice Nutrition 0.000 abstract 1
- 208000026451 salivation Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 17
- 210000002700 urine Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000034507 Haematemesis Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000001780 epistaxis Diseases 0.000 description 5
- 208000006750 hematuria Diseases 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010001580 Albuminuria Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010043458 Thirst Diseases 0.000 description 3
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000020905 low-protein-diet Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000002513 Flank pain Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- -1 hemostasis Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开一种固肾复方中药制剂,该中药制剂由下述重量份的原料制成:黄芪3-8、山药6-10、生地5-12、水蛭8-15、白茅根7-22、芡实15-20、小蓟5-15、金樱子3-7、茜草6-20、三七4-15、藕节16-33、薏米根14-32、仙鹤草6-19、当归5-15、人参3-10、白术6-15。慢性肾炎患者内服使用,能够降低尿素氮、减少蛋白尿起到固肾功效,具有健脾补肾固涩、收敛止血凉血、清热生津的作用,对慢性肾炎的脾肾虚衰、统摄无权,血溢脉外,精脂下泄等具有显著效果。
Description
技术领域
本发明涉及一种内服降低尿素氮、减少蛋白尿的能够起到固肾功效的复方中药制剂。
背景技术
慢性肾小球肾炎(chronic glomerulonephritis)简称慢性肾炎,系指蛋白尿、血尿、高血压、水肿为基本临床表现,起病方式各有不同,病情迁延,病变缓慢进展,可有不同程度的肾功能减退,最终将发展为慢性肾衰竭的一组肾小球病。由于本组疾病的病理类型及病期不同,主要临床表现可各不相同,疾病表现呈多样化。其临床特点为病程长、演变缓慢,变化多端,预后差。
可采用下列综合治疗:(一)积极控制高血压和减少尿蛋白----高血压的治疗目标:力争把血压控制在理想水平,尿蛋白≥1g/d,血压应控制在125/75mmHg以下,尿蛋白<1g/d,血压控制可放宽到130/80mmHg以下。尿蛋白的治疗目标则为争取减少至<1g/d。(二)限制食物中蛋白及磷入量----肾功能不全氮质血症患者应限制蛋白及磷的入量,采用优质低蛋白饮食或加用必需氨基酸或α-酮酸。(三)应用抗血小板解聚药----大剂量双嘧达莫(300~400mg/d)、小剂量阿司匹林(40~300mg/d)有抗血小板聚集作用,目前结果显示其对系膜毛细血管性肾炎有一定降尿蛋白作用。(四)糖皮质激素和细胞毒药物----一般不主张积极应用。肾脏体积正常,病理类型较轻(如轻度系膜增生性肾炎、早期膜性肾病等),尿蛋白较多,如无禁忌者可试用,无数者逐步撤去。(五)避免加重肾脏损害的因素----感染、劳累、任服及肾毒性药物(如氨基糖营类抗生素、含马兜铃酸中药等)均可能损伤肾脏.导致肾功能恶化,应予以避免。总之,慢性肾炎的治疗应以防止或延缓肾功能进行性恶化、改善或缓解临床症状及防治严重合并症为主要目的,而不以消除尿红细胞或轻微尿蛋白为目标。
发明内容
本发明的目的在于提供一种供慢性肾炎患者内服使用的,能够降低尿素氮、减少蛋白尿起到固肾功效的复方中药制剂。
本发明为了实现上述目的,采用的技术解决方案是:
固肾复方中药制剂,由下述重量份的原料制成:黄芪3-8、山药6-10、生地5-12、水蛭8-15、白茅根7-22、芡实15-20、小蓟5-15、金樱子3-7、茜草6-20、三七4-15、藕节16-33、薏米根14-32、仙鹤草6-19、当归5-15、人参3-10、白术6-15。
进一步,固肾复方中药制剂,由下述重量份的原料制成:黄芪4、山药7、生地10、水蛭12、白茅根16、芡实18、小蓟10、金樱子5、茜草12、三七11、藕节23、薏米根20、仙鹤草15、当归8、人参6、白术11。
本发明选用黄芪、山药、生地、水蛭、白茅根、芡实、小蓟、金樱子、茜草、三七、藕节、薏米根、仙鹤草、当归、人参、白术多味中药制成汤剂或颗粒。其中:黄芪,甘微温,归肝肾经,滋阴补血、益精填髓,用于肝肾阴虚,腰膝酸软、骨蒸潮热、盗汗遗精、内热消渴、血虚萎黄、心悸怔忡、月经不调、崩漏下血、眩晕、耳鸣、须发早白。山药,甘平,补脾养胃,生津益肺,补肾涩精。生地,甘寒,清热凉血、养阴生津,用于热病舌绛烦渴、阴虚内热、骨蒸劳热、内热烦渴、吐血、衄血、发斑发疹。水蛭,咸苦平,有毒,破血、逐瘀、通经,用于症瘕痞块、血瘀经闭、跌打损伤。白茅根,甘寒,凉血止血、清热利尿,用于血热吐血、衄血、尿血、热病烦渴、黄疸、水肿、热淋涩痛,急性肾炎水肿。芡实,干涩平,益肾固精、补脾止泻、祛湿止带,用于梦遗滑精、遗尿尿频、脾虚久泻、白浊、带下。小蓟,甘苦凉,凉血止血、祛瘀消肿,用于衄血、吐血、尿血、便血、崩漏下血、外伤出血、痈肿疮毒。金樱子,酸甘涩平,固精锁尿、涩肠止泻,用于遗精滑精、遗尿尿频、崩漏带下、久泻久痢。茜草,苦寒,凉血、止血、祛瘀、通经,用于吐血、衄血、崩漏下血、外伤出血、经闭淤阻、关节痹痛、跌扑肿痛。三七,甘微苦温,散瘀止血、消肿止痛,用于咯血、吐血、衄血、便血、崩漏、外伤出血、胸腹刺痛、跌扑肿痛。藕节,甘涩平,止血、消瘀,用于吐血、尿血、咯血、崩漏。薏米根,甘淡凉,健脾渗湿、除痹止泻、清热排脓,用于水肿、脾虚泄泻。仙鹤草,苦涩平,收敛止血、截疟、止痢、解毒,用于咳血、吐血、崩漏下血、疟疾、血痢、脱力劳伤、痈肿疮毒、阴痒带下。按一定重量份制成复方中药制剂,内服使用降低尿素氮、减少蛋白尿通过复方中各组成药物的协同作用,具有健脾补肾固涩、收敛止血凉血、清热生津的作用,对慢性肾炎的脾肾虚衰、统摄无权,血溢脉外,精脂下泄等具有显著效果。
具体实施方式
下面结合实施例对本发明进行详细说明:
实施例1
固肾复方中药制剂,由下述重量份的原料制成:黄芪3、山药6、生地5、水蛭8、白茅根7、芡实15、小蓟5、金樱子3、茜草6、三七4、藕节16、薏米根14、仙鹤草6、当归5、人参3、白术6。
实施例2
固肾复方中药制剂,由下述重量份的原料制成:黄芪8、山药10、生地12、水蛭15、白茅根22、芡实20、小蓟15、金樱子7、茜草20、三七15、藕节33、薏米根32、仙鹤草19、当归15、人参10、白术15。
实施例3
固肾复方中药制剂,由下述重量份的原料制成:黄芪4、山药7、生地10、水蛭12、白茅根16、芡实18、小蓟10、金樱子5、茜草12、三七11、藕节23、薏米根20、仙鹤草15、当归8、人参6、白术11。
固肾复方中药制剂的制作方法:
以上十六味药物,先取三七,粉碎成粗颗粒,加水浸泡过夜,再加入黄芪、山药、生地、水蛭、白茅根、芡实、小蓟、金樱子、茜草、藕节、薏米根、仙鹤草、当归、人参、白术,加水煎煮2次,每次1.5小时,滤过,合并滤液,减压浓缩至相对密度为1.05~1.10(60℃),放冷,加乙醇至含醇量达70%,放置过夜,滤过,减压回收乙醇,并继续浓缩至相对密度为1.30~1.35(60℃)的稠膏,减压干燥,即得。
取上述稠膏,粉碎,过80目筛,加入微晶纤维素,二氧化硅,加淀粉,混匀,以90%乙醇制粒,干燥,压制成片,包薄膜衣,即得固肾复方中药颗粒。
为表明本发明中药制剂的治疗效果,进行以下对比说明:
1、临床资料
病例选择标准
纳入标准:(1)年龄在18~65岁的男性或女性;(2)符合慢性肾炎诊断标准,其参照WHO慢性肾炎诊断标准。①慢性肾炎诊断标准;②慢性肾炎临床分期标准;③中医证候诊断参照《中药新药治疗慢性肾炎的临床研究指导原则》的标准。(3)中医辩证属于参照《中药新药临床研究指导原则》以及固肾泄浊颗粒的处方、功能主治制定的脾肾虚衰、统摄无权,血溢脉外,精脂下泄证型。
排除标准:(1)诊断为急性肾功能衰竭患者;(2)妊娠或准备妊娠及哺乳期女;(3)合并有心、脑、肺、肝、造血系统等严重疾病,或有恶性肿瘤、活动性结核病等消耗性疾病的患者,乙肝检查提示e抗原阳性者,或肾移植术后者;(4)精神病患者、不能合作者。
2、一般资料
观察病例均为2010年06月到2011年10月青岛经济技术开发区第一人民医院住院及门诊患者,有完整病例资料,共128例。采用完全随机设计方案,应用随机数字表法,按患者就诊的先后顺序将其随机分为治疗组78例,男48例,女30例,年龄18~65岁,平均(46.2±12.8)岁,对照组50例,男28例,女22例,年龄19~63岁,平均(45.0±14.6)岁,各组患者一般资料及治疗前血尿、Scr、BUN水平和24hUpr经均衡性比较,差异均无显著性意义(P>0.05),具有可比性。
3、治疗方法
治疗组在调节血压,控制饮食基础上,给予固肾复方中药颗粒,温水冲服,每日2次,2个月为一个疗程。
对照组采用低盐优质低蛋白饮食,调节血压,常规激素治疗及其它对症治疗。
4、观察指标
临床症状与体征:乏力、疲倦、纳差、腰部疼痛以及舌苔脉象等,实验室检查指标如:治疗前后血肌酐(Scr)、血尿素氮(BUN)以及24小时尿蛋白定量(24hUpr)。
5、疗效评价
参照《中药新药临床研究指导原则》中中药新药治疗慢性肾炎临床研究指导原则并结合临床经验拟定疗效评定标准。临床痊愈:临床症状、体征消失或基本消失,主要理化指标正常。显效:临床症状、体征明显改善,主要理化指标基本正常。有效:临床症状、体征均有好转,主要理化指标基本正常。无效:临床症状、体征均无明显改善,甚或加重。
6、统计学方法
统计学处理使用SPSS13.0统计软件包,所有计量数据先进行方差齐性分析,证实方差齐后采用()表示,组内比较应用t检验,等级资料采用Ridit分析,P<0.05视为有统计学意义。
疗效评价
根据一定的疗效评价标准,评价疗效为:治疗组痊愈0例,显效41例,有效30例,无效7例;对照组痊愈0例,显效18例,有效17例,无效15例。
两组间比较差异无显著性(P>0.05)。
表1两组疗效比较
注:与对照组相比,P<0.05。
表2服用本发明药物临床症状、体征疗效比较
注:治疗组与对照组比较总有效率有显著差异P<0.05。
表3服用本发明药物治疗前后血肌酐、血尿素氮及24小时尿蛋白定量变化比较
注:两组治疗前与治疗后血肌酐、血尿素氮及24小时尿蛋白定量比较有显著差异P<0.01,两组间治疗后结果比较,差异无显著性P>0.05。
关于不良反应
观察期内治疗组有部分病例服药后有轻微的胃部不适、大便次数增多等反应,适当减少剂量或饭后服药后大多消除,可继续进行观察;对照组,偶有高钙血症发生,适当减少维生素D的摄入量后,可消除症状,继续进行观察。治疗组为6.41%(5/78);对照组6.00%(3/50),各组间不良反应发生率比较,差异无统计学意义(P>0.05)。
综上所述,以上应用本发明药物对78例慢性肾炎患者做治疗观察,取得显著疗效如表1,而且治疗前后肝肾心功能及血液生化、大小便检查,均未发现明显毒副作用,说明本发明药物服用安全,对人体无毒害作用。
Claims (2)
1.固肾复方中药制剂,其特征在于,由下述重量份的原料制成:黄芪3-8、山药6-10、生地5-12、水蛭8-15、白茅根7-22、芡实15-20、小蓟5-15、金樱子3-7、茜草6-20、三七4-15、藕节16-33、薏米根14-32、仙鹤草6-19、当归5-15、人参3-10、白术6-15。
2.根据权利要求1所述的固肾复方中药制剂,其特征在于,由下述重量份的原料制成:黄芪4、山药7、生地10、水蛭12、白茅根16、芡实18、小蓟10、金樱子5、茜草12、三七11、藕节23、薏米根20、仙鹤草15、当归8、人参6、白术11。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101218936A CN102648969B (zh) | 2012-04-24 | 2012-04-24 | 固肾复方中药制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101218936A CN102648969B (zh) | 2012-04-24 | 2012-04-24 | 固肾复方中药制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102648969A true CN102648969A (zh) | 2012-08-29 |
CN102648969B CN102648969B (zh) | 2013-12-04 |
Family
ID=46691200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012101218936A Expired - Fee Related CN102648969B (zh) | 2012-04-24 | 2012-04-24 | 固肾复方中药制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102648969B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102872313A (zh) * | 2012-10-05 | 2013-01-16 | 张丙梅 | 一种治疗过敏性紫癜肾炎的中药益气滋肾汤 |
CN103316232A (zh) * | 2013-05-20 | 2013-09-25 | 缪长法 | 一种治疗肾虚的中药及其制备方法 |
CN105749021A (zh) * | 2016-04-29 | 2016-07-13 | 青岛大学附属医院 | 用于治疗慢性肾小球肾炎血尿的中药制剂 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1899537A (zh) * | 2006-07-27 | 2007-01-24 | 张晓涤 | 太芪复肾液 |
CN101396506A (zh) * | 2008-10-09 | 2009-04-01 | 刘运波 | 一种治疗慢性肾小球肾炎的中药 |
KR20090058366A (ko) * | 2007-12-04 | 2009-06-09 | 경희대학교 산학협력단 | 항암제 부작용 억제작용과 항암활성을 갖는 신규한 한약재조성물 |
CN102028897A (zh) * | 2010-12-08 | 2011-04-27 | 山西医科大学第一医院 | 一种治疗肾小球源性血尿的中成药及其制备方法 |
CN102068585A (zh) * | 2011-01-05 | 2011-05-25 | 中国人民解放军第三七一医院 | 一种治疗慢性肾炎、肾病综合症的中药复方制剂 |
-
2012
- 2012-04-24 CN CN2012101218936A patent/CN102648969B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1899537A (zh) * | 2006-07-27 | 2007-01-24 | 张晓涤 | 太芪复肾液 |
KR20090058366A (ko) * | 2007-12-04 | 2009-06-09 | 경희대학교 산학협력단 | 항암제 부작용 억제작용과 항암활성을 갖는 신규한 한약재조성물 |
CN101396506A (zh) * | 2008-10-09 | 2009-04-01 | 刘运波 | 一种治疗慢性肾小球肾炎的中药 |
CN102028897A (zh) * | 2010-12-08 | 2011-04-27 | 山西医科大学第一医院 | 一种治疗肾小球源性血尿的中成药及其制备方法 |
CN102068585A (zh) * | 2011-01-05 | 2011-05-25 | 中国人民解放军第三七一医院 | 一种治疗慢性肾炎、肾病综合症的中药复方制剂 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102872313A (zh) * | 2012-10-05 | 2013-01-16 | 张丙梅 | 一种治疗过敏性紫癜肾炎的中药益气滋肾汤 |
CN102872313B (zh) * | 2012-10-05 | 2013-10-30 | 张丙梅 | 一种治疗过敏性紫癜肾炎的中药益气滋肾汤 |
CN103316232A (zh) * | 2013-05-20 | 2013-09-25 | 缪长法 | 一种治疗肾虚的中药及其制备方法 |
CN105749021A (zh) * | 2016-04-29 | 2016-07-13 | 青岛大学附属医院 | 用于治疗慢性肾小球肾炎血尿的中药制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN102648969B (zh) | 2013-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102342992B (zh) | 一种用于治疗失眠的中药组合物及其制剂的制备方法 | |
CN105920514A (zh) | 治疗代谢综合征的中药组合物 | |
CN104524337A (zh) | 一种治疗口腔溃疡的中药 | |
CN101214315B (zh) | 一种预防和治疗妇科出血的药物及其制备方法 | |
CN102648976B (zh) | 延缓慢性肾衰的药物 | |
CN102648969B (zh) | 固肾复方中药制剂 | |
CN104524071A (zh) | 一种治疗原发性肾病的药物组合物及其用途 | |
CN101797369B (zh) | 一种治疗胃无力症的中药组合物 | |
CN104257982A (zh) | 一种治疗黄褐斑的中药制剂 | |
CN103479969A (zh) | 一种治疗癫狂病的药物及其制备方法 | |
CN106421666A (zh) | 一种治疗肝郁肾虚型卵巢早衰的药物组合物 | |
CN102688434B (zh) | 一种治疗糖尿病的中药 | |
CN102552753A (zh) | 一种治疗子宫肌瘤的中药组合物 | |
CN102343019B (zh) | 一种用于治疗闭经的中药组合物及其制剂的制备方法 | |
CN101618201A (zh) | 一种治疗外阴粘膜白斑的药物 | |
CN102793874B (zh) | 降低狼疮肾炎患者血尿和蛋白尿的中药制剂 | |
CN103223151B (zh) | 一种增白祛斑的中药组合物及其制剂的制备方法 | |
CN101375955B (zh) | 一种用于治疗不射精症的通精制剂及其制备方法 | |
CN101385818B (zh) | 治疗黄体功能不足导致的不孕症的助孕制剂及其制备方法 | |
CN100411681C (zh) | 缩短坐月子时间及治疗人流后遗症产后风的药物 | |
CN104623415A (zh) | 一种治疗肾病的药物组合物及其用途 | |
CN104189615B (zh) | 一种治疗崩漏的中药制剂及其制备方法 | |
CN102755518A (zh) | 治疗复发性流产的药物方剂 | |
CN102861261A (zh) | 改善恶性肿瘤晚期患者生存质量的中药制剂 | |
CN102657727B (zh) | 一种治疗结肠炎的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 Termination date: 20140424 |